FORT MILL, S.C. – June 18, 2019 – Diversey announced today that the Environmental Protection Agency (EPA) has approved the addition of Candida auris (C. auris) to the master label of Oxivir® 1, in both its ready-to-use and wipes formats. Oxivir 1 is effective against C. auris and a broad spectrum of pathogens in just 1 minute.
Oxivir 1 is the first non-bleach disinfectant specifically approved as effective against C. auris by the EPA. The EPA recognizes that C. auris is a serious public health threat, particularly in healthcare settings, and until now, there have been no EPA-approved products specifically registered to control C. auris. Oxivir 1 products have now been tested and passed EPA’s review to secure registration of this emerging, and difficult-to-kill pathogen. This applies to both RTU and Wipes, EPA registration Nos. 70627-74 and 70627-77, respectively.
According to the CDC, C. auris is an emerging fungus that presents a serious global health threat. C. auris is of concern as it is often multidrug-resistant, meaning that it is resistant to multiple antifungal drugs commonly used to treat Candida infections. C. auris has caused outbreaks in healthcare settings. It is important to quickly identify C. auris in a hospitalized patient so that healthcare facilities can take special precautions to stop its spread.
Oxivir 1, powered by Accelerated Hydrogen Peroxide® (AHP®) technology, is effective against a broad range of bacteria, enveloped and non-enveloped viruses, TB and fungi (now including C. auris) in one minute or less. The product leads Diversey’s lineup of fast, effective, responsible and sustainable disinfectant solutions with disinfectant claims against 75+ key pathogens. Like other members of the Oxivir family, Oxivir 1 is non-irritating to skin and eyes, and carries the best possible safety rating. The one-step solution, designed for use in healthcare environments, is tough enough to clean and disinfect surfaces and equipment in one pass while being gentle on staff and surfaces.